BBHvsIGIB
VanEck Biotech ETF against iShares 5-10 Year Investment Grade Corporate Bond ETF — the fee, the flows, the book, and a year head-to-head.
Head to head
| BBH | IGIB | |
|---|---|---|
| Expense ratio | 0.35% | 0.040% |
| Assets | $488M | $18.6B |
| Net flow, 1 month | +$3M | +$565M |
| Net flow, 1 year | −$23M | +$3.6B |
| Return, YTD | +25.5% | -6.9% |
| Return, 1 year | +37.0% | -7.3% |
| Avg daily volume | 12K | 3.8M |
| Holdings | 26 | 2744 |
| Listed | Nov 23, 1999 | Jan 5, 2007 |
| Options market | Yes | Yes |
MARKED CELLS LEAD ON THAT LINE · LOWER FEE, LARGER ASSETS, STRONGER FLOWS & RETURNS